Oxford University Press - Online Resource Centres

Farne, Norris-Cervetto & Warbrick-Smith: Oxford Cases in Medicine & Surgery

Hyperlinked bibliography

Click on the links below to view the references from the book for Chapters 10, 16, 18 and 19 with active links to online journal articles. Please note that some of the sites you will be directed to may require a username and password to access the full text online article.

Chapter 10

Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJJ, Cuddy TE et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New Engl J Med, 327: 669–677 [PubMed: 1386652].

SOLVD Investigators (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New Engl J Med, 325: 293–302.

Pitt, B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. (2000) Effect of losartan compared with captoprilon mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet, 3551: 1582–1587 [DOI: 10.1016/S0140-6736(00)02213-3].

Cohn JN, Tognoni G (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med, 345: 1667–1675 [DOI: 10.1056/NEJMoa010713] [PubMed: 11759645].

Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM et al. (1997) Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol, 13: 1166–1174 [PubMed: 9444298].

Doughty RN, Rodgers A, Sharpe N, MacMahon S (1997). Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J, 18: 560–565 [PubMed: 9129883].

CIBIS-II Investigators (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 353: 9–13 [DOI: 10.1016/S0140-6736(99)90443-9].

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J et al. (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. J Am Med Assoc, 283: 1295–1302 [DOI: 10.1001/jama.283.10.1295].

Pitt, B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New Engl J Med, 341: 709–717 [DOI: 10.1056/NEJM199909023411001] [PubMed: 10471456].

Chapter 16

Andersson RE, Olaison G, Tysk C, Ekbom A (2001). Appendectomy and protection against ulcerative colitis. New Engl J Med, 344: 808–814 [DOI: 10.1056/NEJM200103153441104] [PubMed: 11248156].

Baron S, Turck D, Leplat C et al. (2005) Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut, 54: 357–363 [DOI: 10.1136/gut.2004.054353] [PubMed: 15710983].

Hallas J, Gaist D, Sorensen HT (2004). Does appendectomy reduce the risk of ulcerative colitis? Epidemiology, 15: 173–178 [DOI: 10.1097/01.ede.0000112208.22339.4a] [PubMed: 15127909].

Russel MG, Dorant E, Brummer RJ et al. (1997) Appendectomy and the risk of developing ulcerative colitis or Crohn’s disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology,113: 377–382 [DOI: 10.1053/gast.1997.v113.pm9247453] [PubMed: 9247453].

Radford-Smith GL, Edwards JE, Purdie DM et al. (2002) Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut, 51: 808–813 [DOI: 10.1136/gut.51.6.808] [PubMed: 12427781].

Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenik J (2008). The risk of developing Crohn’s disease after an appendectomy: a meta-analysis. Am J Gastroenterol, 103: 2925–2931 [DOI: 10.1111/j.1572-0241.2008.02118.x] [PubMed: 18775018].

Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J, Frisch M (2007). The risk of developing Crohn’s disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut, 56: 1387–1392 [DOI: 10.1136/gut.2007.121467] [PubMed: 17494106].

Chapter 18

UKSAT Investigators (1998). Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet, 352: 1649–1655 [DOI: 10.1016/S0140-6736(98)10137-X].

Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW et al. (2002) Immediate repair compared with surveillance of small abdominal aortic aneurysms. New Engl J Med, 346: 1437–1444 [DOI: 10.1056/NEJMoa012573] [PubMed: 12000813].

Holdgate A, Pollock T (2004). Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ, 328: 1401 [DOI: 10.1136/bmj.38119.581991.55] [PubMed: 15178585].

Chapter 19

Sturmer, T, Glynn RJ, Lee IM, Christen WG, Hennekens CH (2000). Lifetime cigarette smoking and colorectal cancer incidence in the Physicians_Health Study I. J Natl Cancer Inst, 92: 1178–1181 [DOI: 10.1093/jnci/92.14.1178] [PubMed: 10904092].

Paskett ED, Reeves KW, Rohan TE, Allison MA, Williams CD, Messina CR et al. (2007) Association between cigarette smoking and colorectal cancer in the Women’s Health Initiative. J Natl Cancer Inst, 99: 1729–1735 [DOI: 10.1093/jnci/djm176] [PubMed: 18000222].

Wolin KY, Lee IM, Colditz GA, Glynn RJ, Fuchs C, Giovannucci E (2007). Leisure-time physical activity patterns and risk of colon cancer in women. Int J Cancer, 121: 2776–2781 [DOI: 10.1002/ijc.23009] [PubMed: 17722094].

Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T et al. (2003) Dietary fi bre in food and protection against colorectalcancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet, 361: 1496–1501 [DOI: 10.1016/S0140-6736(03)13174-1] [PubMed: 12737858].

Michels KB, Fuchs CS, Giovannucci E, Colditz GA, Hunter DJ, Stampfer MJ, Willett WC (2005). Fiber intake and incidence of colorectal cancer among 76,947 women and 47,279 men. Cancer Epidemiol Biomarkers Prev, 14: 842–849 [DOI: 10.1158/1055-9965.EPI-04-0544] [PubMed: 15824154].

Flossmann E, Rothwell PM (2007). Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet, 369: 1603–1613 [DOI: 10.1016/S0140-6736(07)60747-8] [PubMed: 17499602].

Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE et al. (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. J Am Med Assoc, 294: 47–55 [DOI: 10.1001/jama.294.1.47].

Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH (1993). Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst, 85: 1220–1224 [DOI: 10.1093/jnci/85.15.1220] [PubMed: 8331682].